Editas Medicine Inc

Healthcare
$9.35
-0.22 (2.30%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Open PricePrev. CloseVolumeAvg. Volume
$9.43$9.571,931,7052,032,490

Fundamentals

Market Cap$658.10M
P/B Ratio1.6
P/E Ratio-3.3
Enterprise Value$468.70M
Div. Yield0.00%
Book Value6.03
EPS(TTM)-2.94
ROE-41.30%
Understand Fundamentals

About the Company

Editas Medicine is a clinical-stage biotechnology firm developing CRISPR–Cas9 gene-editing treatments. Editas is headquartered in Cambridge, Massachusetts, with offices in Boulder, Colorado. Editas was founded in the year 2013 under the name Gengine, Inc. by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners, and Flagship Ventures; the name was later changed to the current one. Editas with Allergan was the first to try to alter DNA within a person's body using CRISPR. Editas revised its agreement with Allergan's parent company, AbbVie, and recovered full rights to their portfolio of eye disease treatment medicines, including EDIT-101 for the treatment of LCA10. In Boulder, Colorado, the firm is constructing new chemical facilities.;
OrganisationEditas Medicine Inc

Company Financials

*All values are in Million $
No Graph Data To Display
Quarterly
Yearly

Similar Stocks

COMPANYMARKET PRICECLOSE PRICEMARKET CAP
Want to invest in US Stocks?
Signup with Groww to get started
Login / Register
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 3.6.9
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI